Clinical studies

Cyto-Barr is developing innovative therapies targeting EBV in various EBV-associated cancer types, and is involved in phase-I clinical studies for the treatment of nasopharyngeal carcinoma, which is endemic in certain parts of Asia and Indonesia.

In the Netherlands such studies have already started and in Indonesia we are preparing such clinical studies. We also actively pursue screening studies for the early identification of NPC, in order to improve treatment options.

The strategy of Cyto-Barr is always focused on partnerships, also in this case, we are looking for partners in order to continue and implement our methods and findings to find a cure for NPC.